Feb 29 |
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
|
Feb 28 |
Centogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plunge
|
Feb 28 |
CENTOGENE Explores Strategic Alternatives
|
Feb 28 |
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
|
Jan 24 |
CENTOGENE Receives French Research Tax Credit Accreditation
|
Jan 23 |
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
|
Jan 18 |
Centogene says FY revenue is expected to be between €48.5 million €49.0 million
|
Jan 18 |
CENTOGENE Announces Preliminary Full Year 2023 Revenue
|
Dec 19 |
CENTOGENE Announces Voting Results of Extraordinary General Meeting
|
Dec 13 |
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
|